Clinical trial
Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
NCT00035581 · AIM ImmunoTech Inc., Industry · Terminated
Key facts
| NCT number | NCT00035581 |
|---|---|
| Title | Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART |
| Official title | A Multi-Center, Randomized, Controlled Study of the Biological Actions of Ampligen as an Adjunct to HAART in HIV Disease |
| Lead sponsor | AIM ImmunoTech Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Seropositivity, HIV Infection |
| Intervention type | Drug |
| Interventions | poly I-poly C12U |
| Enrollment | 16 |
| Start date | May 1, 2001 |
| Primary completion | Sep 1, 2005 |
| Completion | Sep 1, 2005 |
| First posted | May 6, 2002 |
| Last update posted | Apr 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: